Brava Diagnostics ^Company

Brava Diagnostics develops and commercializes acute care diagnostic products based on the MBio diagnostics rapid testing platform. It is seeking seed financing to fund product development for rapid multiplex point-of-care tests for acute care settings. The core platform uses evanescent planar waveguide technology was developed by MBio. Products have been commercialized for applications outside of human health. Brava's in-vitro diagnostics applications will be for cardiac markers, a $2.3 billion worldwide market. Our first indications will be to assess chest pain and shortness of breath in the emergency department. The next assays will address sepsis, the highest cost disease state in U.S. health systems.